Investing

IPO Preview for the Week of June 30

IPO
Thinkstock
The coming week will not match the initial public offering (IPO) action we saw last week, with some 11 companies joining the ranks of publicly traded firms, but we do expect one new firm and six holdovers from last week to price shares and begin trading in the short week leading up to the July Fourth holiday.

According to Renaissance Capital, 145 IPOs have priced in the United States so far this year, up 57.6% from a year ago. Total proceeds raised come to $31.4 billion, up more than 52% from 2013. So far in June, IPO proceeds have totaled $7.9 billion, trailing only April with $8 billion for the highest monthly total so far this year. The 2013 IPO total came in at $54.9 billion, the highest total in the past 10 years. The first half of 2014 has already put $31.4 billion into the coffers of new publicly traded companies.

There are no blockbuster IPOs on tap for the week of June 30, certainly nothing as closely watched as last Friday’s GoPro Inc. (NASDAQ: GPRO) IPO. Here is a brief look at each of the coming week’s IPOs.

Ambrx Inc. is a biotechnology company developing protein therapeutics. The company plans to offer 5.4 million shares in an IPO price range of $12 to $14. This IPO was delayed a week. Pricing and trading dates are given as “day-to-day.” The stock will trade on the Nasdaq under the ticker symbol AMBX.

GlobeImmune Inc. is a biopharma firm developing treatments for cancer and other diseases. The company plans to offer 1.6 million shares at a price range of $15 to $17. This IPO was also delayed a week. Pricing and trading dates are given as “day-to-day.” The stock will trade on the Nasdaq under the ticker symbol GBIM.

ALSO READ: Why GoPro Keeps on Chugging!

Investar Holding Corp. is a bank holding company based in Baton Rouge, La. The company plans to offer 2.9 million shares in an expected price range of $15 to $17. Shares are expected to price Monday and begin trading Tuesday on the Nasdaq under the ticker symbol ISTR.

KineMed Inc. is a commercial stage biotech firm that plans to offer 4.5 million shares in an IPO range of $6.50 to $7.50. This IPO was also delayed a week. Pricing and trading dates are given as “day-to-day.” The stock will trade on the Nasdaq under the ticker symbol KNMD.

Microlin Bio Inc. is a development stage diagnostics and therapeutic company that expects to offer 6 million shares in a price range of $4.50 to $5.50. This IPO has been postponed in each of the past two weeks. Pricing and trading dates are expected this coming week, but no firm dates have been given. The stock will trade on the Nasdaq under the ticker symbol MCLB.

Minerva NeuroSciences Inc. is a clinical-stage biopharma company that plans to offer 5.5 million shares in a price range of $10 to $12. This IPO was also delayed a week. Pricing and trading dates are expected this coming week, but no firm dates have been given. The stock will trade on the Nasdaq under the ticker symbol NERV.

Taggares Agriculture Corp. plans to acquire, redevelop and operate profitable farmland in the Pacific Northwest. The company plans to sell 7 million shares in a price range of $6 to $7. This IPO was also delayed a week. The company plans to price the shares on Monday and begin trading Tuesday on the Nasdaq under the ticker symbol TAG.

ALSO READ: America’s Most Unusual Public Companies

Get Ready To Retire (Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Get started right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.